Sacramento, CA

The trials here

What the 6 trials at this site are about, from their registry records.

Conditions

• Diabetic eye disease5 trials
• Macular degeneration4 trials

Phase

• Phase 1/22 trials
• Phase 2/32 trials
• Phase 11 trial
• Phase 21 trial

Status

• Completed3 trials
• Active, not recruiting2 trials
• Recruiting1 trial

Lead sponsor

• EyeBiotech Ltd.5 trials
• Ollin Biosciences, Inc.1 trial

Running trials

• Recruiting

  A Dose-masked Study of Intravitreal Remigromig (EYE103) in Participants With NVAMD or Macular Edema Following BRVO

  NCT07205887· Phase 2· EyeBiotech Ltd.· Source

  Contact: Charles Miller, MD PhD

• Active, not recruiting

  A Study of 2 Doses of Remigromig (EYE103) Compared With Ranibizumab (0.5 mg) in Participants With DME

  NCT06957080· Phase 2/3· EyeBiotech Ltd.· Source

• Active, not recruiting

  A Study to Evaluate the Efficacy and Safety of 2 Doses of Remigromig (EYE103) Compared With Ranibizumab (0.5 mg) in Participants With DME

  NCT06571045· Phase 2/3· EyeBiotech Ltd.· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Macular degeneration1 recruiting

Closed trials

• Completed

  A Phase 1b Study to Assess the Safety, Tolerability, Pharmacokinetics, and Exploratory Efficacy of Intravitreal OLN324

  NCT07484074· Phase 1· Ollin Biosciences, Inc.· Source

• Completed

  A 2-part Study Consisting of a Multiple Ascending Dose Safety Study in Participants With Macular Edema Following Branch Retinal Vein Occlusion and a Dose-finding Safety and Preliminary Efficacy Study in Participants With Either Diabetic Macular Edema or Neovascular Age-related Macular Degeneration

  NCT06664502· Phase 1/2· EyeBiotech Ltd.· Source

• Completed

  A 2-part Study Consisting of Multiple Ascending Dose (MAD) Safety Study, and a Dose-finding Masked Study to Assess the Safety and Efficacy of Intravitreal (IVT) Remigromig (EYE103) in Patients With Diabetic Macular Edema (DME) or Neovascular Age-related Macular Degeneration (NVAMD)

  NCT05919693· Phase 1/2· EyeBiotech Ltd.· Source